clioquinol has been researched along with Aging in 8 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clioquinol is a metal chelator that has beneficial effects in several cellular and animal models of neurodegenerative diseases as well as on Alzheimer disease patients." | 5.35 | The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. ( Branicky, R; Carroll, M; Guimond, MP; Hayes, S; Hekimi, S; Hihi, A; McBride, K; Stepanyan, Z; Wang, Y, 2009) |
| " We also describe how the development of therapeutic agents designed to modulate metal bioavailability has provided promising results in the treatment of Alzheimer's disease." | 2.43 | Therapeutic treatments for Alzheimer's disease based on metal bioavailability. ( Barnham, KJ; Bush, AI; Crouch, PJ; White, AR, 2006) |
| " The present study was designed to investigate the effect of metal ionophores on long term administration of zinc in D-galactose induced senescent mice." | 1.43 | Possible role of metal ionophore against zinc induced cognitive dysfunction in D-galactose senescent mice. ( Bharti, K; Majeed, AB; Prakash, A, 2016) |
| "Clioquinol is a metal chelator that has beneficial effects in several cellular and animal models of neurodegenerative diseases as well as on Alzheimer disease patients." | 1.35 | The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. ( Branicky, R; Carroll, M; Guimond, MP; Hayes, S; Hekimi, S; Hihi, A; McBride, K; Stepanyan, Z; Wang, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Pretsch, D | 1 |
| Rollinger, JM | 1 |
| Schmid, A | 1 |
| Genov, M | 1 |
| Wöhrer, T | 1 |
| Krenn, L | 1 |
| Moloney, M | 1 |
| Kasture, A | 1 |
| Hummel, T | 1 |
| Pretsch, A | 1 |
| Konishi, T | 1 |
| Hayashi, K | 1 |
| Sugiyama, H | 1 |
| Adlard, PA | 1 |
| Sedjahtera, A | 1 |
| Gunawan, L | 1 |
| Bray, L | 1 |
| Hare, D | 1 |
| Lear, J | 1 |
| Doble, P | 1 |
| Bush, AI | 2 |
| Finkelstein, DI | 1 |
| Cherny, RA | 1 |
| Bharti, K | 1 |
| Majeed, AB | 1 |
| Prakash, A | 1 |
| Wang, Y | 1 |
| Branicky, R | 1 |
| Stepanyan, Z | 1 |
| Carroll, M | 1 |
| Guimond, MP | 1 |
| Hihi, A | 1 |
| Hayes, S | 1 |
| McBride, K | 1 |
| Hekimi, S | 1 |
| Kaur, D | 1 |
| Rajagopalan, S | 1 |
| Andersen, JK | 1 |
| Crouch, PJ | 1 |
| Barnham, KJ | 1 |
| White, AR | 1 |
| Matsuda, M | 1 |
| Yanagisawa, N | 1 |
| Tsukada, N | 1 |
1 review available for clioquinol and Aging
| Article | Year |
|---|---|
Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Biological Availability; Brain; Clioquinol | 2006 |
7 other studies available for clioquinol and Aging
| Article | Year |
|---|---|
Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans.
Topics: Aging; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modi | 2020 |
The Aggravation of Depression with Aging in Japanese Patients with Subacute Myelo-optico-neuropathy (SMON).
Topics: Aged; Aged, 80 and over; Aging; Asian People; Clioquinol; Depressive Disorder; Female; Humans; Male; | 2017 |
A novel approach to rapidly prevent age-related cognitive decline.
Topics: Aging; Animals; Behavior, Animal; Biomarkers; Cell Count; Clioquinol; Cognition Disorders; Dendritic | 2014 |
Possible role of metal ionophore against zinc induced cognitive dysfunction in D-galactose senescent mice.
Topics: Administration, Oral; Aging; Amyloid beta-Peptides; Animals; Clioquinol; Cognition Disorders; Dose-R | 2016 |
The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1.
Topics: Aging; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chelating Agents; Clioquino | 2009 |
Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease.
Topics: Aging; Animals; Apoferritins; Chelating Agents; Clioquinol; Dopamine; Gene Expression Regulation; Ir | 2009 |
[Subsets of peripheral blood lymphocytes and ageing in patients with SMON].
Topics: Aged; Aging; Clioquinol; Humans; Leukocyte Count; Lymphocyte Subsets; Middle Aged; Myelitis; Nervous | 1991 |